Form 4: Stoke Therapeutics Director Acquires Stock Options

Arthur Tzianabos, a director at Stoke Therapeutics, acquired stock options exercisable for 7,639 shares of common stock.

Summary

• Arthur Tzianabos, a director of Stoke Therapeutics, Inc., filed a Form 4 on June 7, 2024, reporting a transaction.
• On June 5, 2024, Tzianabos acquired stock options for 7,639 shares of Stoke Therapeutics common stock at an exercise price of $16.41.
• The options vest on the earlier of June 5, 2025, or the date of the issuer's next annual meeting of its stockholders, contingent upon continued service to the issuer.
• Following the transaction, Tzianabos directly owns 7,639 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a stock option grant, which is neither overwhelmingly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotech industry to align their interests with those of shareholders.
• The vesting schedule of one year or the next annual meeting is also typical.
• Comparing the size of the grant to those of directors at similar-sized biotech companies (e.g., companies with similar market capitalization and stage of development) would provide further context.

Stakeholder Impact

• The acquisition of stock options by a director can positively impact shareholders by aligning management's interests with the company's long-term success.

Key Dates